All these data suggest that IL-33 may be a promising adjuvant to generate effective T cell-mediated protective immunity against cancer, with potential applications in CRC treatment through the improved efficacy of 5-FU-based therapies. This evidence concerns the gene IL33 and colorectal carcinoma.